Invitation to Roche Analyst Event at ASCO 2019 - Monday, 3 June 2019

Roche and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that Roche has withdrawn its Premerger Notification and Report Form under the Hart-Scott-Rodino Act (the “HSR Act”) in connection with Roche’s pending acquisition of Spark pursuant to its previously announced tender offer to purchase all of the outstanding shares o f common stock (the “Shares”) of Spark for USD 114.50 per Share, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchase dated March 7, 2019 (as it may be amended and supplemented from time to time, the “Offer”).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news